Results 21 to 30 of about 2,662,368 (270)

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. [PDF]

Pathol Oncol Res, 2020
NTRK gene fusions affecting the tropomyosin receptor kinase (TRK) protein family have been found to be oncogenic drivers in a broad range of cancers. Small molecule inhibitors targeting TRK activity, such as the recently Food and Drug Administration-approved agent larotrectinib (Vitrakvi®), have shown promising efficacy and safety data in the treatment
Wong D, Yip S, Sorensen PH.
europepmc   +5 more sources

Inhibition of Adult Hippocampal Neurogenesis Plays a Role in Sevoflurane-Induced Cognitive Impairment in Aged Mice Through Brain-Derived Neurotrophic Factor/Tyrosine Receptor Kinase B and Neurotrophin-3/Tropomyosin Receptor Kinase C Pathways. [PDF]

Front Aging Neurosci, 2022
Sevoflurane anesthesia induces cognitive impairment, which may lead to perioperative neurocognitive disorders (PND). However, the factors and molecular mechanism underlying this impairment remains unclear.
Xu L, Guo Y, Wang G, Sun G, Sun W, Li J, Li X, Wu J, Zhang M.   +8 more
europepmc   +2 more sources

Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway [PDF]

Cancer Medicine
Introduction A neurotrophic tropomyosin receptor kinase (NTRK)‐tyrosine kinase inhibitor (TKI) has shown dramatic efficacy against malignant tumors harboring an NTRK fusion gene.
Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike   +12 more
doaj   +2 more sources

The Role of the Second Extracellular Loop of Norepinephrine Transporter, Neurotrophin-3 and Tropomyosin Receptor Kinase C in T Cells: A Peripheral Biomarker in the Etiology of Schizophrenia. [PDF]

Int J Mol Sci, 2021
The neurobiology of schizophrenia is multifactorial, comprising the dysregulation of several biochemical pathways and molecules. This research proposes a peripheral biomarker for schizophrenia that involves the second extracellular loop of norepinephrine
Rodrigues-Amorim D, Iglesias-Martínez-Almeida M, Rivera-Baltanás T, Fernández-Palleiro P, Freiría-Martínez L, Rodríguez-Jamardo C, Comís-Tuche M, Vallejo-Curto MDC, Álvarez-Ariza M, López-García M, de Las Heras E, García-Caballero A, Olivares JM, Spuch C.   +13 more
europepmc   +2 more sources

Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights [PDF]

Molecules
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively.
Amol T. Mahajan, Shivani, Ashok Kumar Datusalia, Carmine Coluccini, Paolo Coghi, Sandeep Chaudhary   +5 more
doaj   +2 more sources

Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors. [PDF]

Ann Transl Med, 2019
The past decade has witnessed a paradigm shift in the treatment of cancer, moving from ‘one size fits all’ to a more precision medicine-based approach owing to the development of molecular diagnostic technologies capable of identifying an increasing number of actionable genomic alterations in the tumor tissue and circulating tumor DNA.
Mamdani H, Jalal SI.
europepmc   +4 more sources

A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma [PDF]

PeerJ, 2019
Neurotrophic receptor tyrosine kinase 2 (NTRK2) is a member of the tropomyosin receptor kinase family associated with the tumor development. However, the detailed function of NTRK2 in lung cancer, especially in lung adenocarcinoma (LUAD), is still not ...
Xiang Wang, Zhijie Xu, Xi Chen, Xinxin Ren, Jie Wei, Shuyi Zhou, Xue Yang, Shuangshuang Zeng, Long Qian, Geting Wu, Zhicheng Gong, Yuanliang Yan   +11 more
doaj   +5 more sources

A tropomyosin-receptor kinase-fused gene mutation associates with vacuolar myopathy. [PDF]

Neurol Genet, 2018
A 44-year-old Caucasian man presented with a 7-year history of upper and lower limb muscle fasciculations and cramps, progressive asymmetric weakness, muscle atrophy, and length-dependent sensory loss. His parents (deceased), 3 older siblings, and 3 children had no history of neurologic symptoms, including weakness and sensory symptoms, with the ...
Madigan NN, Tracy JA, Litchy WJ, Niu Z, Chen C, Ling K, Milone M.   +6 more
europepmc   +5 more sources

Compounds originating from the edible mushroom Auricularia auricula-judae inhibit tropomyosin receptor kinase B activity. [PDF]

Heliyon, 2023
Shahar O, Pereman I, Khamisie H, Ezov N, Danay O, Khattib A, Schweitzer R, Khatib S, Mahajna J.   +8 more
europepmc   +2 more sources

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. [PDF]

Acta Pharm Sin B, 2021
Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y, Chen Y, Ouyang L.   +8 more
europepmc   +2 more sources